Patents Represented by Attorney, Agent or Law Firm The firm of Gordon W. Hueschen
  • Patent number: 5955454
    Abstract: The invention relates to a nasal pharmaceutical preparation suitable for nasal administration containing a progestogen and a methylated .beta.-cyclodextrin having a degree of substitution of between 0.5 and 3.0 and hard gelatin capsules containing the same.
    Type: Grant
    Filed: September 11, 1995
    Date of Patent: September 21, 1999
    Assignee: Adir et Compagnie
    Inventor: Franciscus Merkus
  • Patent number: 5948806
    Abstract: The present invention relates to the use of efaroxan and its derivatives for the preparation of a medicinal product intended for the treatment of Parkinson's disease.
    Type: Grant
    Filed: March 26, 1997
    Date of Patent: September 7, 1999
    Assignee: Pierre Fabre Medicament
    Inventors: Francis Colpaert, Michael Briley, Thierry Imbert
  • Patent number: 5945566
    Abstract: New amino compounds of formula: ##STR1## wherein n and Y are as defined in the description, in racemic form or in the form of optical isomers.and addition salts thereof with pharmaceutically acceptable acids.Those compounds may be used as medicaments.
    Type: Grant
    Filed: April 9, 1998
    Date of Patent: August 31, 1999
    Assignee: Adir et Compagnie
    Inventors: Jean-Louis Peglion, Mark Millan
  • Patent number: 5919784
    Abstract: A compound of general formula (I): ##STR1## where A, X, R.sub.1, Y, n and Ar are defined in the description. Medicinal products containing the same are useful as D.sub.4 receptor Ligands.
    Type: Grant
    Filed: November 7, 1997
    Date of Patent: July 6, 1999
    Assignee: Adir Et Compagnie
    Inventors: Daniel Lesieur, Pascal Carato, Jean-Paul Bonte, Patrick Depreux, Daniel-Henri Caignard, Mark Millan, Adrian Newman-Tancredi, Pierre Renard, Marie-Claire Rettori
  • Patent number: 5919801
    Abstract: New N-substituted cyclic amines of formula: ##STR1## wherein: X, R.sub.1, R.sub.2 and R are as defined in the description, their optical and geometric isomers and physiologically tolerable salts thereof. The compounds of the invention are powerful PDE4 inhibitors and can be used therapeutically.
    Type: Grant
    Filed: September 19, 1997
    Date of Patent: July 6, 1999
    Assignee: Adir et Compagnie
    Inventors: Alain Dhainaut, Andre Tizot, Emmanuel Canet, Michel Lonchampt
  • Patent number: 5919283
    Abstract: An inert gas bubble-actuated molten metal pump is located between one section of a metal-melting furnace and a second section to pump molten metal from the one section, wherein the molten metal is at a higher temperature, into the second section, wherein the molten metal is at a lower temperature, and its effluent is directed into contact with metal chips being charged into the second section, thereby assisting in the more rapid melting of the chips into the molten metal mass in the second section. The inert gas employed to actuate the molten metal pump is captured beneath a heat-resistant and flame-resistant cover located above the exit port of the pump and over a substantial portion of the molten metal mass in the second section, thereby providing a non-oxidizing atmosphere at the surface of the molten metal mass or pool beneath said cover.
    Type: Grant
    Filed: November 6, 1996
    Date of Patent: July 6, 1999
    Assignee: Premelt Pump, Inc.
    Inventor: Larry D. Areaux
  • Patent number: 5919814
    Abstract: The invention relates to compound of general formula (I): ##STR1## wherein: Z represents O or CH.sub.2n is from 0 to 4R, X and Y are as defined in the description, andA represents ##STR2## wherein R.sup.1, R.sup.2, R.sup.6, R.sup.7 and T' are as defined in the description,and medicinal products containing the same are useful in treating or in preventing melatoninergic disorders.
    Type: Grant
    Filed: April 24, 1998
    Date of Patent: July 6, 1999
    Assignee: Adir et Compagnie
    Inventors: Gerald Guillaumet, Isabelle Charton, Ahmed Mamai, Pierre Renard, Bruno Pfeiffer, Philippe Delagrange, Beatrice Guardiola
  • Patent number: 5919791
    Abstract: The compounds of formula: ##STR1## in which: R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7 and A are as defined in the description, their optical isomers and N-oxides and addition salts thereof with a pharmaceutically acceptable acid or base, and their use as anti-tumour agents.
    Type: Grant
    Filed: December 29, 1997
    Date of Patent: July 6, 1999
    Assignee: Adir et Compagnie
    Inventors: Claude Guillonneau, Emile Bisagni, Yves Charton, Ghanem Atassi, Alain Pierre, Stephane Leonce
  • Patent number: 5900233
    Abstract: An anion-binding hydrophilic epichlorohydrin and 1-(3-aminopropyl)imidazole copolymeric bile acid sequestrant, pharmaceutical compositions thereof, and use thereof in the treatment of ailments or conditions in which a bile acid sequestrant and inhibitor of fat absorption is indicated.
    Type: Grant
    Filed: October 16, 1997
    Date of Patent: May 4, 1999
    Inventor: Charles E. Day
  • Patent number: 5900247
    Abstract: The present invention relates to a new mucoadhesive pharmaceutical composition which makes possible the prolonged release of active pharmaceutical principles in the buccal cavity or via the transmucosal route.
    Type: Grant
    Filed: December 27, 1996
    Date of Patent: May 4, 1999
    Assignee: Adir et Compagnie
    Inventors: Isabelle Rault, Gerald Pichon
  • Patent number: 5889045
    Abstract: A compound of formula (I): ##STR1## in which: R.sub.1 represents alkyl,R.sub.2, R.sub.4 and R.sub.5, which may be identical or different, represent hydrogen or alkyl,R.sub.3 represents any one of the groups as defined in the description,X represents carbonyl or methylene,Y represents hydrogen or alkyl or aryl,A represents single bond or alkylphenyl,R.sub.6 represents any one of the groups as defined in the description, its isomers as well as its addition salts with a pharmaceutically acceptable acid or base,and medicinal productes containing the same are useful in the treatment of diabetes and complications of diabetic disease.
    Type: Grant
    Filed: November 25, 1997
    Date of Patent: March 30, 1999
    Assignee: Adir et Compagnie
    Inventors: Timothee Muller, Claudie Moulin, Muriel Duflos, Sylvie Robert-Piessard, Guillaume Le Baut, Alain Tonnerre, Daniel-Henri Caignard, Dominique Manechez, Pierre Renard
  • Patent number: 5889164
    Abstract: This invention provides a novel chromanol glycoside which is a water soluble antioxidant excellent in heat and pH stability and production method thereof. It is a chromanol glycoside represented by the general formula (1): ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, and R.sup.4 independently are a hydrogen atom or a lower alkyl group, R.sup.5 is a hydrogen atom, a lower alkyl group, or a lower acyl group, X is a monosaccharide residue or an oligosacoharide residue, providing the hydrogen atom of the hydroxyl group of saccharide residue may be substituted by a lower alkyl group or a lower acyl group, n is an integer in the range of 0 to 4, and m is an integer in the range of 1 to 6.
    Type: Grant
    Filed: September 27, 1995
    Date of Patent: March 30, 1999
    Assignee: CCI Corporation
    Inventors: Hironobu Murase, Tsutomu Kunieda, Tetsuya Tsujii
  • Patent number: 5888542
    Abstract: The invention relates to a matrix tablet for the prolonged release of the sodium salt of tianeptine which ensures a continuous and uniform release of the active ingredient after administration by the oral route.
    Type: Grant
    Filed: April 23, 1997
    Date of Patent: March 30, 1999
    Assignee: Adir Et Compagnie
    Inventors: Bruno Huet de Barochez, Patrick Wuthrich
  • Patent number: 5886166
    Abstract: A retroviral vector comprising a retrovirus with infectivity for birds and/or mammals in which at least part of the genomic RNA sequences carrying information for the production of viral proteins required in trans for retroviral replication have been replaced by one or more sequences carrying information to be introduced in a target cell chromosome, characterized in that the primer binding site (PBS) has been modified to a sequence that does not allow strong base pairing with the 3' end or other priming sequence in any naturally occurring tRNA. The present application is directed to the tRNA-like primer.
    Type: Grant
    Filed: November 15, 1996
    Date of Patent: March 23, 1999
    Inventors: Finn Skou Pedersen, Anders Henrik Lund, Jette Lovmand, Poul J.o slashed.rgensen, Mogens Duch
  • Patent number: 5885581
    Abstract: A dermatological composition for use in improving the appearance of scars comprising 20-30 parts by weight of polyethylene glycol 200, 0.005-0.03 parts by weight of preservative, 0.05-0.2 parts by weight of sorbic acid, 0.5-2 parts by weight of allantoin, 1-3 parts by weight of xanthan gum, 5-15 parts by weight of fluid onion extract (Extract Allium Cepa), dermatologically-acceptable aqueous carrier 55-65 parts by weight, perfume oil optional, for a total of 100 parts by weight, in the form of a light milky gel, and a method of improving the appearance of a scar comprising the step of applying to the scar a dermatologically-effective amount thereof.
    Type: Grant
    Filed: September 11, 1997
    Date of Patent: March 23, 1999
    Assignee: Merz, Incorporated
    Inventor: Deepak Massand
  • Patent number: 5877190
    Abstract: A compound of formula (I): ##STR1## wherein: R.sub.1 represents unsubstituted or substituted cycloalkyl, phenyl, naphthyl, heterocyclic, alkyl or alkenyl,A represents a bond, oxygen, sulphur, a group ##STR2## a group ##STR3## or a group ##STR4## wherein Rc represents hydrogen, alkyl or cycloalkyl, R.sub.2 represents halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, cycloalkyl, formyl, carboxy, alkylcarbonyl, cycloalkylcarbonyl, alkoxycarbonyl, cycloalkyloxycarbonyl, optionally substituted carbamoyl, optionally substituted amino, formylamino, cyano, optionally substituted amidino, hydroxyaminomethyl, amide oxime, hydrazono, or a group selected from: ##STR5## wherein R.sub.21, R.sub.22 and R.sub.23 are as defined in the description, R.sub.
    Type: Grant
    Filed: October 3, 1997
    Date of Patent: March 2, 1999
    Assignee: Adir et Compagnie
    Inventors: Alain Dhainaut, Guillaume Poissonnet, Emmanuel Canft, Michel Lonchampt
  • Patent number: 5871004
    Abstract: A bowstring retention and release mechanism includes a housing or body with a head rotatable 360.degree. therein and a lower forward projection extending out of the head providing an upward bowstring-engaging surface upon which the bowstring can rest and which, in combination with a downwardly-extending segment of a lever arm, which also extends forwardly outside of the head and which is pivoted within the head, provides for retention and release of the bowstring. The lever arm is biased upwardly for release of the bowstring but is maintained in downward bow-string-retention position by a rearwardly-extending protuberance which cooperates with an activator which is slidably mounted within the head and which is forwardly biased so as to cam the protuberance up an upward incline to a forward step on the activator, thereby preventing the lever arm from upward movement into bowstring-release position.
    Type: Grant
    Filed: October 17, 1997
    Date of Patent: February 16, 1999
    Inventor: Geary L. Garvison
  • Patent number: 5866587
    Abstract: Compound of formula (I): ##STR1## in which: m, n, which are identical or different, represent 0, 1 or 2,R.sub.1, R.sub.2, which are identical or different, represent hydrogen, optionally substituted alkyl, aryl, or form with the carbon atom carrying them carbonyl or (C.sub.3 -C.sub.7)cycloalkyl,R.sub.3 represents hydrogen, alkyl, hydroxyl or aryl,R.sub.4 represents any of the groups as defined in the description,X represents --SO.sub.2 --, --CO-- or --SO.sub.2 NH--,R.sub.5 represents optionally substituted alkyl, (C.sub.3 -C.sub.7)cycloalkyl, aryl or heterocyclic,A represents an aryl ring or a heterocycle,its isomers as well as its addition salts with a pharmaceutically acceptable acid or base and medicinal products containing the same are useful as metalloprotease inhibitors.
    Type: Grant
    Filed: April 25, 1997
    Date of Patent: February 2, 1999
    Assignee: Adir Et Compagnie
    Inventors: Guillaume de Nanteuil, Joseph Paladino, Georges Remond, Ghanem Atassi, Alain Pierre, Gordon Tucker, Jacqueline Bonnet, Massimo Sabatini
  • Patent number: 5866411
    Abstract: A retroviral vector comprising a retrovirus with infectivity for birds and/or mammals in which at least part of the genomic RNA sequences carrying information for the production of viral proteins required in trans for retroviral replication have been replaced by one or more sequences carrying information to be introduced in a target cell chromosome, characterized in that the primer binding site (PBS) has been modified to a sequence that does not allow strong base pairing with the 3' end or other priming sequence in any naturally occurring tRNA.
    Type: Grant
    Filed: September 8, 1995
    Date of Patent: February 2, 1999
    Inventors: Finn Skou Pedersen, Anders Henrik Lund, Jette Lovmand, Poul J.o slashed.rgensen, Mogens Duch
  • Patent number: 5863925
    Abstract: The invention relates to the use of sulbutiamine and pharmaceutical compositions thereof for the treatment of Parkinson's Disease, Schizophrenia, alcoholism, and dysthymia.
    Type: Grant
    Filed: October 3, 1997
    Date of Patent: January 26, 1999
    Assignee: Adir et Compagnie
    Inventors: Helene Ollat, Alain Le Ridant, Laurent Perret